A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.
The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer Cell, showed that the drugs, called PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses within their ability to copy their DNA.
The first-in-class PARG inhibitor PDD00017273, was discovered in the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of The University of Manchester, as part of a targeted program to discover PARG inhibitors for the clinic.
This program is currently being progressed through a collaboration with IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies.
These findings are promising for patients diagnosed with ovarian cancer, the sixth commonest cause of cancer in women in the UK and causes more than 4,000 deaths each year.
“Sadly, for the majority of women diagnosed with ovarian cancer, the cancer relapses within 12 to 18 months of their first treatment, and so there is a pressing need to develop new therapies to treat this condition,” said lead scientist Stephen Taylor from The University of Manchester.
Through a collaborative effort across The University of Manchester including the Cancer Research UK Manchester Institute and The Christie , Manchester, scientists were able to screen ovarian cancer cells for specific genes that, when knocked out, would bring about PARG-inhibitor sensitivity. Through their work, the team identified the key genes that made cancer cells sensitive to PDD00017273 were those involved in DNA replication.
“Before a cell divides, it must replicate its DNA. This critical process ensures the necessary amount of DNA is passed on to its daughter cells. Our research has shown that an inherent defect in the ability of an ovarian cancer cell to replicate its DNA can be exploited by the PARG inhibitor to kill the cancer cell,” Ph.D. student Nisha Pillay said. “This new class of drugs is potentially very exciting and could signal a new way to help patients diagnosed with ovarian cancer in which their tumor has not responded to standard treatments.”
The research team then went on to show that the PARG inhibitor can also be used in combination with other clinically accessible drugs, such as CHK1 and WEE1 inhibitors, to kill ovarian cancer cells that were taken directly from samples from patients treated at The Christie.
“We hope this work will provide further impetus for developing a PARG inhibitor for use in human trials, and also biomarkers that can be used to select the most appropriate patients to receive such treatments in the future,” Dr. Robert Morgan, from The Christie, said.
Filed Under: Oncology
